Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Supernus Pharmaceuticals achieves record revenues, faces generic competition in 2022

Supernus Pharmaceuticals delivered a strong financial performance in 2022, driven by record revenues and successful product launches.
While facing challenges from generic competition, the company's focus on growth brands and pipeline assets offers opportunities for future expansion and innovation.
Strategic financial management and market adaptation will be crucial for Supernus Pharmaceuticals to navigate challenges and capitalize on growth prospects in 2023.
With a solid financial foundation and a commitment to innovation, the company is poised to pursue growth opportunities and enhance shareholder value in the pharmaceutical sector.

Supernus Pharmaceuticals reports Q1 revenue growth, faces Trokendi XR challenges

Supernus Pharmaceuticals delivered a mixed performance in Q1 2023, with strong revenue but challenges in Trokendi XR sales.
The company's financial strength, strategic guidance revisions, and pipeline progress position it for future growth.
Opportunities lie in leveraging cash reserves, driving key product sales, and advancing pipeline programs for sustained growth.
Addressing challenges in Trokendi XR sales and maintaining competitive positioning will be crucial for Supernus Pharmaceuticals' success.

Supernus Pharmaceuticals reports Q2 growth driven by Qelbree success

Supernus Pharmaceuticals showcased strong performance in Q2 2023, driven by Qelbree and GOCOVRI growth, despite Trokendi XR sales decline.
While facing challenges with Trokendi XR, the company's pipeline progress and strategic focus on key products offer growth opportunities.
Management's financial guidance reiteration for 2023 reflects confidence in the company's ability to navigate challenges and capitalize on strengths.
Overall, Supernus Pharmaceuticals remains positioned for growth through product innovation and market expansion strategies.

Supernus Pharmaceuticals reports robust Q3 performance amidst revenue challenges

Supernus Pharmaceuticals delivered a strong performance in Q3 2023 driven by Qelbree and GOCOVRI, showcasing revenue growth and promising product milestones.
While facing challenges with Trokendi XR sales decline and financial losses, the company maintains a positive outlook with revised full-year guidance and a solid cash position.
Opportunities lie in leveraging product strengths, advancing pipeline studies, and utilizing available resources to sustain growth and navigate challenges effectively.

Supernus Pharmaceuticals reports robust earnings, eyes CNS market expansion

Supernus Pharmaceuticals delivered strong financial performance in Q4 2023 and full year 2023, supported by record sales and stable earnings.
The company's transition to growth products, strong cash reserves, and strategic focus on CNS present a promising outlook for future growth.
While challenges exist in product transitions and market dynamics, Supernus is well-positioned to capitalize on opportunities in the CNS space.
By leveraging its strengths, addressing challenges, and seizing opportunities, Supernus Pharmaceuticals aims for sustained growth and market leadership.

Supernus Pharmaceuticals reports robust Q1 performance amidst pipeline opportunities

Supernus Pharmaceuticals demonstrated strong performance in Q1 2024, driven by Qelbree's growth, while facing challenges in the Parkinson's franchise.
The company's financial stability is evident with a healthy cash position and reiterated full-year revenue guidance.
Exciting opportunities exist in the CNS pipeline, but addressing setbacks like the FDA response for SPN-830 is crucial.
Strategic actions are needed to navigate the impact of generics on existing products and capitalize on upcoming catalysts.

Supernus Pharmaceuticals reports strong Q2 earnings and raises 2024 guidance

Supernus Pharmaceuticals demonstrated solid financial performance and growth in Q2 2024, driven by key products and pipeline advancements.
While facing regulatory uncertainties and operational challenges, the company's strong cash position and raised guidance signal resilience and strategic foresight.
Opportunities lie in expanding the CNS pipeline, optimizing gross-to-net deductions, and leveraging financial strength for future growth initiatives.

Supernus Pharmaceuticals reports strong Q3 performance and raises revenue guidance

Supernus Pharmaceuticals demonstrated robust financial performance and product growth in Q3 2024, driven by key products and pipeline advancements.
While facing challenges with certain product sales and pricing strategies, the company remains well-positioned for future opportunities and revenue expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.

Bunge Global SA

National Vision Hlds

Ryder System

Trinseo PLC

As bond yields retreated to 1.52% after trading as high as 1.62% yesterday, the indices popped. Meanwhile, Q.ai's Artificial Intelligence Systems have crunched the numbers to bring you today's best top buys.

Top Stocks To Buy Today As Bond Yields Retreat And Growth Stocks Rebound

Best Buy

Lennar

Grand Canyon Education

XPO Logistics

Stocks saw mild gains due to optimism after the $1.9 trillion stimulus bill passed the Senate over the weekend. In the meantime, Q.ai's Artificial Intelligence has crunched the numbers to bring you today's top buys.

Top Stocks To Buy Today Amid Stimulus Optimism

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q4 2020 Results - Earnings Call Transcript

Coherus BioSciences

Ironwood Pharma

Their recent struggles may soon give way to rising market interest and more lucrative returns.

3 Undervalued Biotechs Worth Adding to Your Watch List

ROCKVILLE, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Cowen 41st Annual Health Care Conference on Wednesday, March 3, 2021, at 12:20 p.m. ET.

Supernus to Present at Cowen Healthcare Conference

Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 8.06% over the past year to $0.57, which beat the estimate of $0.52.

Supernus Pharmaceuticals: Q4 Earnings Insights

ROCKVILLE, Md., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today reported financial results for the fourth quarter and full year of 2020, and associated Company developments.

Supernus Announces Fourth Quarter and Full Year 2020 Financial Results

Supernus Pharmaceuticals saw its IBD SmartSelect Composite Rating rise to 96 Thursday, up from 94 the day before. The post Top-Rated Stocks: Supernus Pharmaceuticals Sees Composite Rating Climb To 96 appeared first on Investor's Business Daily.

Top-Rated Stocks: Supernus Pharmaceuticals Sees Composite Rating Climb To 96

ROCKVILLE, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it received notice from the U.S. Food and Drug Administration (FDA) that the company's New Drug Application (NDA) resubmission for SPN-812 for the treatment of ADHD in pediatric patients is considered a Class I resubmission thereby assigning a timeline of two months for review by the FDA and establishing a new Prescription Drug User Fee Act (PDUFA) target action date in early April 2021.

Supernus Receives FDA Notice Assigning Early April 2021 PDUFA Date for SPN-812 NDA

ROCKVILLE, Md., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it has resubmitted its New Drug Application (NDA) for SPN-812 for the treatment of ADHD in pediatric patients. The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the NDA in November 2020 indicating that the review cycle for the application was incomplete and that the application was not ready for approval in its present form. Supernus and the FDA held a Type A meeting in January 2021 to discuss the CRL and the requirements for the NDA resubmission.

Supernus Resubmits New Drug Application for SPN-812 for the Treatment of ADHD in Pediatric Patients

ROCKVILLE, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present at the J.P. Morgan 39th Annual Healthcare Conference on Thursday, January 14, 2021, at 9:10 a.m. ET, and will be available for virtual investor meetings.

Supernus to Present at J.P. Morgan 39th Annual Healthcare Conference

It has been eight months since we last looked in on a promising biopharma concern named Supernus Pharmaceuticals. Some significant news has posted since then including some recently disclosed encouraging study news.

Sizing Up Supernus Pharmaceuticals

The company announced positive results from a clinical trial.

Why Supernus Pharmaceuticals Stock Is Rising Today

The shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) are up 17.7% at $26.50 at last check, after its experimental drug for attention deficit hyperactivity disorder (ADHD), SPN-812, met its main goal in a late-stage study in adults.

Supernus Stock Soars on Experimental ADHD Drug Update

Supernus Pharmaceuticals Inc (NASDAQ: SUPN) announced Monday that its SPN-812 — a commercial treatment for patients with Attention Deficit Hyperactivity Disorder (ADHD), exhibited positive topline results in late-stage trials. What Happened Supernus claimed that the daily active 600mg dose of the SPN-812 cleared the primary and secondary efficacy endpoints.

Why Supernus Shares Rallied 24% After-Hours On Tuesday

Supernus Pharmaceuticals Inc. shares jumped more than 20% in after-hours trading Tuesday after the company revealed positive results from a study of its potential drug for attention deficit hyperactivity disorder, or ADHD. Supernus announced Tuesday afternoon that a phase 3 study of the drug, known as SPN-812, on adults achieved its targeted endpoint.

Supernus stock surges after ADHD-drug study results

ROCKVILLE, Md., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced positive topline results from a Phase III study of SPN-812 in adults (P306) for the treatment of attention deficit hyperactivity disorder (ADHD).

Supernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHD

Amphastar Pharma

Amneal Pharmaceuticals

Biogen

Horizon Pharma

Phibro Animal Health

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1 2021.

Top Pharmaceutical Stocks for Q1 2021

Let's see if Supernus Pharmaceuticals (SUPN) stock is a good choice for value-oriented investors right now from multiple angles.

Is Supernus Pharmaceuticals (SUPN) a Worthy Stock Now?

NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. (“Supernus or the “Company”) (NASDAQ: SUPN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN

ROCKVILLE, Md., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will participate in a fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020. The Company will also host investor meetings on Thursday, December 3, 2020.

Supernus to Participate in Annual Piper Sandler Healthcare Conference

ROCKVILLE, Md., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present an overview and update, as well as host investor meetings, at the following virtual investor conferences in November 2020.

Supernus to Present at Two November Investor Conferences

ROCKVILLE, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced regulatory updates for SPN-812 (viloxazine hydrochloride) for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age, and SPN-830 (apomorphine infusion pump) for the continuous treatment of motor fluctuations (“on-off” episodes) in Parkinson's disease (PD).

Supernus Provides Regulatory Updates for SPN-812 and SPN-830

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q3 2020 Results - Earnings Call Transcript

Supernus (SUPN) delivered earnings and revenue surprises of 174.07% and 18.11%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

News for Supernus Pharmaceuticals Stock (SUPN)